Novo Uses UK Academia To Feed Diabetes Pipeline Despite Brexit Doubts
Novo Nordisk, which says it still has faith in the UK's life science expertise even in the face of Brexit disruption, plans to establish a new research center at the University of Oxford – but will this be enough to help plump up its lackluster pipeline?
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.